Literature DB >> 18341527

A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure.

Klaus Jung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18341527     DOI： 10.1111/j.1365-2796.2008.01952.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN： 0954-6820            Impact factor:   8.989


× No keyword cloud information.
  3 in total

1.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

2.  How could analyzing the activity of two matrix metalloproteinases unveil the cause of sudden cardiac death.

Authors:  Ivan Sosa; Aron Grubesic
Journal:  Int J Immunopathol Pharmacol       Date:  2016-06-06       Impact factor: 3.219

3.  Plasma tissue inhibitor of matrix metalloproteinase-1 (TIMP-1): an independent predictor of poor response to cardiac resynchronization therapy.

Authors:  Jose María Tolosana; Lluís Mont; Marta Sitges; Antonio Berruezo; Victoria Delgado; Bàrbara Vidal; David Tamborero; Manel Morales; Montserrat Batlle; Eulalia Roig; M Angeles Castel; Félix Pérez-Villa; Miguel Godoy; Josep Brugada
Journal:  Eur J Heart Fail       Date:  2010-04-01       Impact factor: 15.534
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.